-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4

Benzinga·08/14/2026 13:21:13
语音播报
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.